ArticleThe Journal of rheumatology2013
Statin use in giant cell arteritis: a retrospective study.
Article in The Journal of rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Analysis of Emergency Department Visits by Patients With Giant Cell Arteritis: A National Population-Based Study.Cureus · 2023Article
- Cardiovascular lesions in giant cell arteritis.Reumatologia · 2022Review
- Looking ahead: giant-cell arteritis in 10 years time.Therapeutic advances in musculoskeletal disease · 2022Review
- Statins in Neuro-ophthalmology.Neuro-ophthalmology (Aeolus Press) · 2021Review
- Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case-control study.RMD open · 2020Article
- Association between statin use and incidence of relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center retrospective cohort study.Rheumatology international · 2020Observational
- Article
- Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.Rheumatology international · 2017Review
- The Treatment of Giant Cell Arteritis.Current treatment options in neurology · 2017Review
- Lower body mass index is associated with a higher risk of giant cell arteritis: a systematic review and meta-analysis.Annals of translational medicine · 2015Article
- Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012.Seminars in arthritis and rheumatism · 2015Article
- Giant cell arteritis: Current treatment and management.World journal of clinical cases · 2015Review
- High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins.Arthritis research & therapy · 2015Article
- Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study.Arthritis care & research · 2015Article
- Giant cell arteritis and polymyalgia rheumatica: an update.Current rheumatology reports · 2015Review
- Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort.The Journal of rheumatology · 2015Article
- Thrombosis in vasculitis: from pathogenesis to treatment.Thrombosis journal · 2015Article
- Hospitalized infections in giant cell arteritis: a population-based retrospective cohort study.The Journal of rheumatology · 2014Article
- Clinical practice. Giant-cell arteritis and polymyalgia rheumatica.The New England journal of medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objective(1) To examine the association between statin use and giant cell arteritis (GCA); (2) to compare the clinical features and disease course of GCA among statin users and nonusers.
methodsFor this retrospective study, we reviewed the medical records of all patients with biopsy-positive GCA diagnosed between 1998 and 2008. Using a case-control design, we compared the frequency of statin use in GCA patients to non-GCA population-based subjects who were randomly selected and individually matched by sex, age, and calendar year to the GCA cases. Statin use at diagnosis or index date and during followup was abstracted. In subjects with GCA, clinical information at diagnosis and followup was collected.
resultsWe included 594 patients, 297 with GCA (73% female), mean age at diagnosis 75 years. The rate of statin exposure at index date was 18.1% for GCA patients versus 33.3% for controls (p < 0.001). Patients using statins were less likely to develop GCA compared with patients not using statins (OR 0.31, 95% CI 0.15-0.6, p < 0.001), even after adjustment for cardiovascular risk factors. Among patients with GCA, the presenting clinical features and acute-phase reactants were similar in patients receiving statins compared to those not on statin therapy. These 2 groups were also similar with regard to relapse rate, prednisone tapering, and overall survival.
conclusionPatients using statins may be less likely to develop GCA compared to patients who are not using statins. Statin use does not appear to modify the clinical presentation or the course of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.